Retatrutide (GIP/GLP-1/GCG) versus semaglutide (GLP-1 only) — the widest mechanistic gap between two widely-studied incretin research peptides.
This comparison spans two full receptor systems. Retatrutide engages GIP, GLP-1 and glucagon; semaglutide engages only GLP-1.
| Attribute | Retatrutide | Semaglutide |
|---|---|---|
| Receptors | GIP + GLP-1 + GCG | GLP-1 only |
| Weight-endpoint magnitude | Highest published | Well-characterised, lower than triple agonists |
| Trial depth | Phase II | Phase III/IV mature dataset |
| Half-life | ~6 days | ~7 days |
Choosing a research reference peptide
For long-term signalling reference, semaglutide's dataset is the deepest. For maximum mechanistic breadth in a single molecule, retatrutide is the current published leader.
Research use only. All information on this page is provided strictly for in-vitro and laboratory research reference. Nothing in this article is medical, therapeutic, dosing, or performance advice for human or veterinary use.
